Drug maker AstraZeneca, seller of the Seroquel antipsychotic drug, suppressed clinical studies showing its drug significantly increased the risk of diabetes, say internal e-mails.
As Bloomberg is reporting today, employee emails that were unsealed as part of a lawsuit reveal AstraZeneca deliberately hid at least three studies that established a significant link between its Seroquel drug and the onset of diabetes in patients. This fact was blatantly admitted in a 1999 e-mail sent by an AstraZeneca official.